A clinical trial involving sincalide has been updated to withdrawn status as of July 29, 2026. The study, registered as NCT07018804, was titled "Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome."
The trial phase is listed as not applicable. Its current status on record is withdrawn, meaning the study did not proceed as originally registered.
No results or outcome data are included in this update. The event record does not specify a reason for the withdrawal. No efficacy or safety conclusions about sincalide can be drawn from this status change.
Sincalide remains an approved compound, and this update pertains only to the status of this specific registered trial. Readers interested in the mechanisms of airway basal cell dysfunction in bronchiolitis obliterans syndrome may wish to monitor the ClinicalTrials.gov record for any further updates.
For additional context on sincalide, readers can consult the compound overview.